Long non-coding RNAs (lncRNAs) are increasingly recognized as functional units in can-13 cer pathways and powerful molecular biomarkers, however most lncRNAs remain un-14 characterized. Here we performed a systematic discovery of prognostic lncRNAs in 9,326 15 patient tumors of 29 types using a proportional-hazards elastic net machine-learning 16 framework. lncRNAs showed highly tissue-specific transcript abundance patterns. We 17 identified 179 prognostic lncRNAs whose abundance correlated with patient risk and im-18 proved the performance of common clinical variables and molecular tumor subtypes. 19
INTRODUCTION 29
The human genome encodes numerous long non-coding RNAs (lncRNAs) that lack protein-cod-30 ing potential and are sparsely annotated [1, 2] . A recent survey annotated nearly 20,000 high-31
confidence human lncRNA genes of at least 200 nucleotides in length, indicating that lncRNAs 32 are at least as common as protein-coding genes [2] . Globally, lncRNAs are transcribed at lower 33 levels compared to protein-coding genes and exhibit transcript abundance patterns specific to 34 tissue types and developmental stages [1, 3] . lncRNAs are involved in the regulation of cellular 35 processes through multifunctional interactions with the genome, transcriptome and proteome [4, 36 5 ]. Individual lncRNAs are increasingly recognized as key players in diverse biological pro-37 cesses such as chromatin remodeling in X chromosome inactivation [6] , post-transcriptional 38 gene regulation through alternative splicing [7] , and epigenetic silencing through histone modifi-39 cation [8] . Computational analysis of lncRNAs enables systematic functional insights and gene 40 prioritization. For example, k-mer analysis identified non-linear sequence similarities between 41 lncRNAs that were informative of protein-RNA interactions and sub-cellular localization [9] . 42 However, the vast majority of lncRNAs lack functional annotations and most of our knowledge of 43 non-coding genes is based on a few well-studied examples. 44 lncRNAs are increasingly implicated in cancer hallmark pathways such as proliferation, angio-45 genesis, growth suppression, cell motility and immortality [10] . Specific well-studied lncRNAs 46 are now recognized as biomarkers for diagnosis, prognosis and therapy of cancer. The first 47 lncRNA-based biomarker gene PCA3 is specifically expressed in prostate cancer tissue relative 48 to normal prostate tissue [11] and is now used in non-invasive tests that complement standard 49 serum-based tests of prostate-specific antigen [12] . The lncRNA HOTAIR is involved in cancer 50 progression and metastasis through chromatin remodeling and its increased transcript abun-51 dance in breast cancer is a robust predictor of tumor metastasis and patient survival [13] . Tran-52 scriptional profiling of normal and tumor samples has revealed numerous tissue-specific 53 lncRNAs [1, 15, 16] , indicating further potential for discovery and development of cancer bi-54 omarkers based on the noncoding transcriptome. Some lncRNAs are also frequently mutated in 55 cancer genomes and recent studies have identified candidate driver mutations by surveying 56 whole-genome sequencing data in multiple cancer types [17, 18] . Projects such as The Cancer 57 Genome Atlas (TCGA) [19] , International Cancer Genome Consortium (ICGC) [20] , METABRIC 58 [21] and others have accumulated multi-omics datasets and patient clinical profiles for thou-59 sands of cancer samples. These resources have enabled biomarker studies that associated 60 PanCanAtlas dataset [22, 29] ( Supplementary Table 1 ). We identified 5,785 high-confidence 92 lncRNAs that were annotated by both the FANTOM CAT project [2] and the Ensembl database 93 [30] ( Supplementary Table 2 ). We first asked whether the lncRNAs showed tissue-specific 94 transcript abundance patterns in the TCGA pan-cancer dataset. Unsupervised clustering of 95 lncRNA transcriptomes using the UMAP dimensionality reduction algorithm [31] revealed a ro-96 bust grouping of tumor samples by organ systems and histological subtypes (Figure 1A) , akin 97 to multi-omics data of protein-coding genes [29] . For example, the clusters indicated lncRNA-98 based transcriptional similarity of lower-grade gliomas and glioblastomas of the brain (LGG, 99 GBM), colon and rectum adenocarcinomas (COAD, READ), and four types of squamous carci-100 nomas (BLCA, LUSC, HNSC, CESC). Highly tissue-specific lncRNA abundance patterns sug-101 gest that the non-coding transcriptome includes uncharacterized diagnostic and prognostic bi-102 omarkers. 103
As a pilot study of lncRNAs as prognostic markers in human cancers, we associated lncRNA 104 transcript abundance with overall patient survival using Cox proportional-hazards (PH) models. 105
We used individual lncRNAs as predictors in combination with standard clinical variables such 106 as patient age, sex, tumor stage and/or grade available in TCGA. Nearly half of lncRNAs were 107 significantly associated with overall patient survival in at least one cancer type (2,740 of 5,785, 108 47%, Wald test, FDR < 0.05), with the majority of lncRNAs found in kidney renal cell carcinoma 109 (KIRC) and lower-grade glioma (LGG) (Figure 1B) . Most of these lncRNAs were associated 110 with survival in only one cancer type (2,203/2,740 or 80%) , confirming tissue-specificity of 111 lncRNA transcription. The majority of lncRNAs appeared hazardous (81%) as their transcript 112 abundance was associated with poor prognosis. Interestingly, 18% of lncRNAs were zero-di-113 chotomized based on their discrete transcriptional activation patterns, as one group of patients 114 showed high transcript abundance of a given lncRNA while the other patient group showed 115 complete lncRNA silencing. These characteristics suggest a high potential for biomarker discov-116 ery in non-coding cancer transcriptomes. 117
Having identified thousands of survival-associated lncRNAs in the pilot analysis, we asked 118 whether these represented robust and independent signals of transcript abundance. We per-119 formed an exhaustive co-expression analysis of all 1,116,955 pairs of survival-correlated 120 lncRNAs in their corresponding cancer types and found that a large fraction (35%) were signifi-121 cantly correlated in transcript abundance (Spearman correlation, rho > ±0.3 and FDR < 0.05; 122 Figure 1C ). As expected, lncRNA pairs with matching prognostic risk were often positively cor-123 related while pairs of lncRNAs with opposing risk correlated negatively. Thus, this large pool of 124 putatively survival-associated lncRNAs represent a considerably narrower space of transcrip-125 tional signatures that are confounded by factors such as epigenetic or transcriptional co-regula-126 tion, patient clinical characteristics and tumor subtypes. This analysis indicates that many 127 lncRNAs are expected to be transcriptionally correlated with patient survival in statistical tests 128 however their confounders and high rate of co-expression limit their use in prognostic models 129 designed to evaluate previously unseen patients. A systematic computational strategy is needed 130 to distinguish representative and robust lncRNAs as prognostic biomarkers. 131 data splits for training and testing. Each model initially included a pool of nominally survival-as-139 sociated lncRNAs for the given cancer type that were evaluated based on training data (Cox PH 140 P < 0.05). The subsequent feature selection step extracted a subset of lncRNAs as high-confi-141 dence predictors for that cross-validation iteration. These multivariate models were then evalu-142 ated on test data using the concordance index (c-index), an accuracy measure for risk models 143 with censored survival data [33] . We also fitted baseline models as controls that included only 144 clinical variables as predictors (e.g., tumor stage, grade, patient age and sex, as available in 145 TCGA), and additional combined models that included as predictors both the set of clinical vari-146 ables and all pre-selected transcript abundance profiles of lncRNAs. We evaluated the entire 147 series of multivariate lncRNA-based survival models trained through cross-validations. 148
Prognostic models of lncRNA-based predictors showed consistently superior performance in 149 terms of concordance index values in nine cancer types, compared to baseline models that only 150 included clinical variables (Wilcoxon rank-sum test, FDR < 0.05; Supplementary Figure 2) . 151
Combining clinical variables and lncRNA transcript abundance profiles as predictors further im-152 proved prognostic performance of our models in 12 of 28 cancer types. To evaluate false-posi-153 tive rates of our strategy, we also generated 100 simulated datasets for each cancer type by 154 randomly reassigning patient survival data within each cohort of a specific cancer type. As ex-155 pected, c-indices from the simulated datasets were consistently lower than those obtained from 156 true data and centered on the performance value of a random predictor (c = 0.5), lending confi-157 dence to our strategy (Supplementary Figure 3) . These observations underline the added 158 value of analyzing lncRNAs as prognostic biomarkers and suggest follow-up validation analyses 159 in additional patient cohorts. 160
We prioritized 179 high-confidence prognostic lncRNAs in 21 cancer types that were detected 161 as strong predictors in at least 50% of cross-validated models following the feature selection 162 step of the elastic net framework (Figure 2A, Supplementary Table 3 ). The majority of 163 lncRNAs (123/179 or 69%) were detected as unfavorable markers with respect to high transcript 164 abundance (median HR = 2.3) while 56 lncRNAs were detected as favorable (median HR = 165 0.48). The largest numbers of prognostic lncRNAs were detected in multiple common cancer 166 types: breast (21), bladder (14), ovarian (14), colorectal (12) and head and neck cancer (12). 167
Lower-grade glioma (12) showed the strongest lncRNA candidates in terms of statistical signifi-168 cance. To quantify the 179 lncRNAs as prognostic markers individually and in combination with 169 commonly used clinical variables, we separately considered each lncRNA regarding its prog-170 nostic model fit and also model performance in cross-validation experiments. The vast majority 171 of individual lncRNAs (173/179) showed significantly higher prognostic accuracy across 1,000 172 cross-validations compared to baseline models comprising common clinical variables, with me-173 dian increase of 0.11 in concordance index (Wilcoxon rank-sum test, FDR < 0.05; Figure 2B ). 174
Thus, our catalogue of lncRNAs provides complementary prognostic information to common 175 clinical variables in a diverse set of human cancers. 176
We verified that our observed prognostic signals were specific to lncRNAs and did not solely re-177 flect the prognostic signals of adjacent protein-coding genes. We identified 147 protein-coding 178 genes located within ±10 kbps of 96/179 lncRNAs, including 106 genes that were antisense to 179 lncRNAs ( Supplementary Table 4 ). Prognostic models of lncRNA transcript abundance profiles 180 exhibited higher concordance measures overall, compared to matching prognostic models of 181 protein-coding genes (Rank-sum test, P = 7.88x10 -22 ; Figure 2C ). lncRNA-based prognostic 182 models showed higher concordance index values in 139/147 cases compared to similar models 183 of adjacent protein-coding genes, with a median improvement of 0.05 in c-index (c=0.58 for 184 lncRNAs vs c=0.53 for protein-coding genes). Thus, the catalogue of prognostic lncRNAs is not 185 transcriptionally confounded by adjacent protein-coding genes and represents a distinct non-186 coding search space for prognostic biomarker discovery. 187 188
Top prognostic lncRNAs in cancer types of unmet need 189
We studied the 179 lncRNAs and the adjacent protein-coding genes for known associations with 190 cancer. For example, CCAT1 (ENSG00000247844) located in the chr8p24 super-enhancer lo-191 cus is known to regulate MYC transcription through chromatin long-range interactions [34] . We 192 found CCAT1 as a marker of poor prognosis in lung adenocarcinoma (LUAD) (HR = 1.9, HR 193 range = 1.4-2.5, Cox PH FDR = 1.6x10 -4 ; Figure 3A) . Overall, the 149 protein-coding genes lo-194 cated within ±10 kbps of the 179 lncRNAs included 10 known cancer genes of the Cancer Gene 195
Census database [35] (BCL10, HEY1, HOXA11, HOXA9, IRS4, LASP1, MYB, NCKIPSD, 196 RNF43, SETD2; Fisher's exact P = 0.050), suggesting that a subset of the prognostic lncRNAs 197 may be involved in the regulation of cancer driver genes through transcription regulatory and 198 chromatin architectural interactions. Improved lncRNA-based survival predictions were found in 199 several cancer types with poor outcomes that currently lack reliable prognostic biomarkers, such 200 as colon, pancreatic and liver cancer. We reviewed the top candidates in these cancer types. 201 BZRAP1-AS1 was found as a top significant lncRNA in the pancreatic adenocarcinoma cohort 202 (PAAD) (ENSG00000265148; also known as TSPOAP1-AS1). Increased RNA abundance of 203 BZRAP1-AS1 associated with improved patient prognosis (HR = 0.39, HR range = 0.23-0.57, 204
Cox PH FDR = 5.2x10 -5 ; Figure 3B ). Interestingly, BZRAP1-AS1 is partially co-located in the 205 genome with RNF43, a known driver gene with frequent mutations in pancreatic cancer (7%) 206 and a potential therapeutic target [36, 37] . RNF43 mRNA abundance alone did not appear prog-207 nostic in our dataset, potentially highlighting an independent function of this lncRNA. BZRAP1-208 AS1 was recently reported as a survival-associated lncRNA in pancreatic cancer using a com-209 plementary transcriptomics dataset [38] , validating our results obtained from the TCGA dataset. 210 AC097468.7 was identified as a top significant lncRNA in the colon adenocarcinoma (COAD) 211 cohort for its unfavorable transcript abundance profile. High abundance of AC097468.7 212 (ENSG00000235024) in a minority of tumors (41/425 or 9.6%; median 1077 FPKM-UQ) was as-213 sociated with worse prognosis (HR = 2.8, HR range = 1.7-4.9, Cox PH FDR = 2.7x10 -4 ; Figure  214 3C), while the majority of tumors in the COAD cohort showed zero transcript abundance of the 215 lncRNA and relatively better prognosis. The intergenic lncRNA is located between the genes 216 NHEJ1 and IHH within 10 kbps of both genes. NHEJ1 is a core component of the non-homolo-217 gous end joining (NHEJ) pathway that conducts DNA double strand break repair and maintains 218 genome stability [39, 40] . Indian hedgehog (IHH) signaling regulates differentiation of colono-219 cytes while epigenetic activation of IHH causes decreased self-renewal of colorectal cancer-initi-220 ating cells and increased sensitivity to chemotherapy [41] [42] . We speculate that the prognostic 221 lncRNA AC097468.7 is involved in the regulation of these pathways through interactions with 222 adjacent protein-coding genes. In summary, these examples demonstrate the potential of our 223 catalogue to develop novel biomarkers and find functional lncRNAs for multiple important can-224 cer types. 225
Computational validation of AC114803.3, CTC-297N7.5 and LINC00324 as prognostic 226 lncRNAs in liver hepatocellular carcinoma 227
To investigate the 12 prognostic lncRNAs in hepatocellular carcinoma of the liver (LIHC), we 228 studied an additional cohort of 42 patient tumors. The validation cohort was derived from the 229 ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) project [20] and was filtered to 230 exclude tumors from TCGA. We found three lncRNAs with matching prognostic scores and sig-231 nificant P-values in both cohorts based on median dichotomization of transcript abundance val-232 ues (AC114803.3, CTC-297N7.5, LINC00324) (Figure 3D-F) . 233 AC114803.3 was identified as a top significant lncRNA in both the discovery and the validation 234 cohorts of liver cancer. Increased transcript abundance of this lncRNA was associated with 235 worse prognosis in the TCGA cohort (HR = 2.6, HR range = 1.7-3.7, Cox PH FDR = 1.8x10 -5 ) 236 and confirmed in the PCAWG validation cohort (HR = 10.6, HR range = 3.1-36, P = 0.0001) 237 ( Figure 3D) . In the discovery cohort, AC114803.3 (ENSG00000230432) showed a discrete acti-238 vation pattern with high transcript abundance in a minority of patients with poor prognosis 239 (84/365 or 23% patient tumors with median 4239 FPKM-UQ) whereas a lack of RNA expression 240 was observed in the other lower-risk group representing the majority of patients (0 FPKM-UQ). 241
The discrete activation pattern was also observed in the validation cohort (11/42 tumors with 242 median 0.093 FPKM-UQ, zero otherwise). AC114803.3 is an antisense lncRNA co-located with 243 the PTPRN gene that encodes a signaling protein and autoantigen in insulin-dependent diabe-244 tes [43] . A previous study found that DNA hypermethylation of PTPRN was associated with in-245 creased progression-free survival in ovarian cancer [44] . DNA hypermethylation is a repressive 246 epigenetic mark inversely correlated with transcription, thus the study provides complementary 247 evidence to our observation of high transcript abundance of the antisense lncRNA AC114803.3 248 as a hazardous prognostic marker. 249
Two lncRNAs CTC-297N7.5 and LINC00324 were also found as markers of improved prognosis 250 of LIHC through validation in the external dataset. Increased transcript abundance of CTC-251 297N7.5 (ENSG00000263400) was associated with improved prognosis in the TCGA cohort 252 (HR = 0.41, HR range = 0.29-0.61, FDR = 3.2x10 -5 ) and validated in the PCAWG cohort (HR = 253 0.16, HR range = 0.032-0.76, P = 0.0080) ( Figure 3E) . CTC-297N7.5 (also known as 254 TMEM220-AS1) is an antisense lncRNA co-located with TMEM220 encoding a poorly charac-255 terized transmembrane protein. This lncRNA has been reported recently as a prognostic factor 256 in hepatocellular carcinoma [45] , further validating our analysis. As the third prognostic lncRNA, 257 increased transcript abundance of LINC00324 (ENSG00000178977) was associated with im-258 proved prognosis in the TCGA LIHC cohort (HR = 0.43, HR range = 0.29-0.62, FDR = 6.0x10 -5 ) 259 and validated in the PCAWG cohort (HR = 0.18, HR range = 0.04-0.84, P = 0.011) ( Figure 3F) . 260
This intergenic lncRNA has been functionally associated with the proliferation of gastric cancer 261 cells [46] . Our computations validation analysis is limited by the available datasets and an over-262 all lower detection of lncRNA transcript abundance in the PCAWG dataset. In summary, compu-263 tational validation of our candidate lncRNAs in additional transcriptomics datasets and inde-264 pendent studies provides further support to these non-coding transcripts as prognostic bi-265 omarkers. 266 267 268
Transcript abundance information of lncRNAs improves prognostic performance of 269 known molecular and clinical tumor features 270
We asked whether the prognostic lncRNAs represented the transcriptomic footprints of well-de-271 fined clinical and molecular tumor subtypes. We investigated the statistical interactions of prog-272 nostic lncRNAs and of various molecular and clinical tumor annotations defined by TCGA [47] . 273
We limited the analysis to a subset of lncRNAs (113/179) that were detected in 12/21 cancer 274 types for which annotations of tumor features or subtypes were available in TCGA. We found 275 224 instances where transcript abundance of lncRNAs (36/113) associated with clinical or mo-276 lecular tumor features (Chi-square test or Spearman correlation test, FDR < 0.05; Figure 4A , 277 Supplementary Table 5 ). As expected, the majority of these features were also prognostic indi-278 vidually in univariate survival analyses (175/224 or 78%, Wald test, FDR < 0.05). The prognostic 279 lncRNAs we identified in lower-grade glioma (LGG) associated with the largest number of mo-280 lecular and clinical features, likely owing to well-defined subtypes of this form of brain cancer. 281
For example, transcript abundance profiles of the majority of prognostic lncRNAs in LGG were 282 significantly associated with documented prognostic features such as IDH mutation status and 283
MGMT promoter methylation [48, 49] . These data indicate that transcript abundance profiles of 284 prognostic lncRNAs capture the transcriptomic signatures of known clinical subtypes and molec-285 ular features, further supporting the utility of these lncRNAs as prognostic biomarkers. 286
We asked whether the lncRNA transcript abundance profiles provided complementary infor-287 mation to clinical and molecular tumor features. We investigated the 224 cases where the 36 288 lncRNA transcript abundance profiles significantly associated with various tumor features, by 289 comparing combined prognostic models (i.e., lncRNAs and tumor features as predictors) with 290 control prognostic models (i.e., only tumor features as predictors) ( Figure 4B) . The majority of 291 combined models (209/224 or 93%) showed improved prognostic performance and model fit 292 To study potential functional associations, we asked whether transcript abundance profiles of 308 prognostic lncRNAs were associated with transcriptome-wide changes in high-risk tumors. For 309 each lncRNA, we identified differentially regulated genes and mapped their biological context 310 using pathway enrichment analysis [50] . The majority of prognostic lncRNAs (121/179 or 68%) 311 associated with clear transcriptional signatures in lncRNA-stratified high-risk tumors, including at 312 least 30 protein-coding genes with a two-fold change in transcript abundance (FDR < 0.05; 313 Supplementary Table 6 ). These genes were enriched in 3,048 GO 314 biological processes and Reactome pathways in total (FDR < 0.01 from g:Profiler; Supplemen-315 tary Table 7 ). The majority of detected pathways (75%) were enriched in the transcriptional sig-316 natures of a few lncRNAs (one to five) while a small subset of processes (5%) related to extra-317 cellular matrix organization were enriched in the signatures of more than 15 lncRNAs. This pan-318 cancer pathway analysis highlights the extent of functional diversity of high-risk tumors stratified 319 by lncRNA abundance. 320
We studied the 12 prognostic lncRNAs identified in lower-grade glioma and evaluated their tran-321 scriptome-wide associations. We used a stringent approach that systematically accounted for 322 the tumor mutation status of IDH1/2 genes, a known marker of improved prognosis in glioma 323 [51] . All groups of lncRNA-stratified high-risk LGG tumors were characterized by transcriptomic 324 differences that were significant beyond IDH mutations (Figure 5A) . To find pathways and pro-325 cesses commonly deregulated in these high-risk tumors, we performed an integrative analysis 326 of the 12 lncRNA-stratified mRNA abundance signatures. This analysis revealed 325 biological 327 processes and pathways that mapped to 1,345 protein-coding genes co-expressed with one or 328 more of the 12 prognostic lncRNAs (ActivePathways [52] FWER < 0.05; Figure 5B ). The path-329 way analysis highlighted 70 known cancer genes that were more frequently differentially ex-330 pressed than expected from chance alone (Fisher's exact test, P = 0.006; including key onco-331 genes EGFR and TERT). The pathway analysis revealed three broad functional themes: devel-332 opmental processes (e.g., forebrain development), immune system (e.g., T-cell activation) and 333 neurotransmitters (e.g., trans-synaptic signaling). The majority of pathways (192/325 or 59%) 334 were deregulated in the transcriptomic signatures of multiple prognostic lncRNAs, however only 335 few pathways were apparent in all lncRNA-based transcriptomic signatures. These prognostic 336 lncRNAs of LGG are co-regulated with diverse processes involved in brain development, neuro-337 transmitter activity and tumorigenesis, suggesting that a subset of lncRNAs modulate cancer-338 related biological processes in brain tumors. 339 HOXA10-AS and HOXB-AS2 defines a malignancy (Figure 5C-D) . In particular, the subset of ~10% LGG patients 361 with no IDH mutations and high lncRNA abundance were stratified as the highest-risk group 362 compared to all other patients. Thus, the two lncRNAs may represent novel molecular bi-363 omarkers of advanced LGGs whose discrete transcriptional activation patterns in combination 364 with IDH mutation status indicate dismal outcome. 365
Transcript abundance of
We quantified the transcriptional activation of HOXA10-AS and HOXB-AS2 in lower-grade glio-366 mas and glioblastomas. Hierarchical transcriptome clustering of HOXA10-AS and HOXB-AS2 367 together with the 118 developmental genes across the LGG and GBM cohorts revealed a malig-368 nancy gradient of gliomas (Figure 5E ). The major low-risk cluster of tumor transcriptomes con-369 tained LGGs with little or no transcription of the two prognostic lncRNAs. In contrast, the cluster 370 of high-risk LGGs was clearly defined by an increased abundance of HOXB-AS2 and HOXA10-371
AS. This high-risk set of LGGs was clustered together with GBMs, while GBMs were defined by 372 even higher transcript abundance of the two prognostic lncRNAs as well as oncogenes such as 373 EGFR and GLI1. In LGG, HOXB-AS2 and HOXA10-AS were characterized by bimodal tran-374 script abundance: high transcript abundance was observed in few tumors (19% and 21% re-375 spectively), and silencing with zero transcript abundance of the two lncRNAs in the majority of 376 tumors. Further, the majority of GBM tumors showed high transcript abundance of HOXB-AS2 377 (68%) and HOXA10-AS (70%) and their overall transcript abundance was higher in GBMs than 378 in LGGs (Supplementary Figure 5) , indicating that HOX-antisense lncRNA expression posi-379 tively correlated with tumor grade. HOXB-AS2 and HOXA10-AS were not significant prognostic 380 in the GBM cohort, perhaps owing to the overall poor prognosis of these advanced tumors 381 (Supplementary Figure 6) . This neurodevelopmental gene signature may represent a tran-382 scriptomic subtype of LGG that is marked by discrete transcriptional activation of the two HOX-383 antisense lncRNAs with prognostic relevance and functional roles. 384
385

HOXA10-AS knockdown in patient-derived glioblastoma cells reduces proliferation and 386 deregulates cell cycle genes and glioma drivers 387
The prognostic and pathway associations of HOXA10-AS transcript abundance prompted us to 388 investigate this lncRNA functionally. We performed a siRNA-mediated knockdown experiment of 389 HOXA10-AS followed by a six-day cell proliferation experiment using the primary patient-derived 390 GBM cell line G797 [53, 54] . To minimize off-target effects on the protein-coding gene HOXA10 391 antisense to the lncRNA, we used two siRNAs against the unique exon three of the lncRNA. 392 siRNA-mediated inhibition of HOXA10-AS led to two-fold reduction in transcript abundance of 393 the lncRNA relative to non-targeted controls (T-test, P ≤ 0.020; Figure 6A ). HOXA10-AS -inhib-394 ited cells showed ~40% lower cell proliferation at the 6-day timepoint (P ≤ 0.0011; Figure 6B) . 395
Transcriptional inhibition of HOXA10-AS and the resulting reduction in cell proliferation was ro-396 bustly observed in experiments conducted with either of the two targeting siRNAs. These find-397 ings indicate the function of HOXA10-AS in regulating cell proliferation in glioma and confirm a 398 recent report on this lncRNA [55] . 399
To further understand the role of HOXA10-AS in the hallmark pathways of glioma, we con-400 ducted whole-transcriptome RNA sequencing (RNA-seq) of HOXA10-AS depleted cells three 401 days after siRNA transfection. We found a pronounced transcriptional response of 2,428 differ-402 entially expressed genes in HOXA10-AS-inhibited cells relative to non-targeted controls (Brown 403 FDR < 0.05, log2 fold-change > 1.2 using TREAT [56]; Figure 6C ). The two targeting siRNA in-404 duced highly correlated transcriptome-wide changes (Pearson correlation test, R = 0.84, P < 10 -405 300 ) and confirmed reduced transcript abundance of HOXA10-AS in siRNA-treated cells (P < 406 0.023, L2FC < -0.95; Figure 6D-E) . We interpreted the transcriptomic changes induced by 407 HOXA10-AS knockdown using pathway enrichment analysis and found 84 biological processes 408 and molecular pathways enriched in the differentially expressed genes (FWER < 0.05 from Ac-409 tivePathways [52]; Figure 6F) . The pathways and processes were associated with 2,108 differ-410 entially expressed genes through the sensitive data fusion approach implemented in Active-411
Pathways. Known cancer genes were significantly enriched (137 observed vs 91 expected, 412
Fisher's exact P = 2.4x10 -7 ) and included 12 up-regulated genes that are well recognized in the 413 biology and mutational driver landscape of glioma (GOPC, RB1, PTEN, STAG2, QKI, MDM2, 414 NBN, PIK3CA, ATRX, HIF1A, ATM, PDGFRA; Figure 6G ) [35, 57, 58] . For example, the en-415 riched GO process regulation of mitotic cell cycle (FWER = 0.03) provides an explanation to our 416 observed phenotype of reduced glioma cell proliferation and implicates HOXA10-AS in the tran-417 scriptional rewiring of cell proliferation pathways. 128 genes of this pathway were deregulated in 418 HOXA10-AS inhibited cells, including two upregulated tumor suppressors RB1 and PTEN. Addi-419 tional enriched pathway themes such as DNA repair (MDM2, NBN, ATRX, ATM), protein ubiqui-420 tination (PTEN, ATM, MDM2, HIF1A), lipid metabolism (PTEN, QKI, PIK3CA, ATM) and TGF-421 beta signaling (HIF1A) suggest further roles of HOXA10-AS in mediating cell proliferation in gli-422 oma. Finally, we asked whether our observed transcriptional and proliferative differences of 423 HOXA10-AS depleted cells would be explained by the antisense homeobox gene HOXA10 that 424 modulates the tumorigenic potential of glioblastoma stem cells [59] . HOXA10 showed no signifi-425 cant differences in transcript abundance in HOXA10-AS depleted cells compared to control-426 transfected cells in RNA-seq data and RT-qPCR assays (Supplementary Figure 7) , suggesting 427 that our functional and transcriptional evidence of altered cell proliferation is specific to the 428 lncRNA HOXA10-AS and is not significantly confounded by any off-target effects of our knock-429 down experiment. In summary, these findings provide functional evidence to one of our pre-430 dicted prognostic lncRNAs as a regulator of hallmark cancer processes in glioma. 431
432
DISCUSSION 433
The current knowledge of cancer driver genes and molecular classifiers is primarily derived from 434 the protein-coding genome while the vast non-coding genome remains understudied. Our find-435 ings of lncRNAs as prognostic factors in multiple cancer types are consistent with the increasing 436 appreciation of lncRNAs in diverse cellular processes and human diseases. Our study highlights 437 a facet of the non-coding genome that has great potential for basic and translational discover-438 ies. Our machine learning analysis identified a subset of lncRNAs as robust predictors of patient 439 survival in cross-validation experiments, suggesting that these transcripts should be further 440 evaluated as prognostic biomarkers in diverse molecular datasets. To establish one lncRNA as 441 a bona fide modulator of cancer hallmark processes, we functionally validated a prominent can-442 didate lncRNA HOXA10-AS in patient-derived glioblastoma cells and observed significantly re-443 duced cell viability upon lncRNA depletion, differential expression of glioma driver genes as well 444 as transcriptome-wide changes enriched in proliferative, DNA damage response and metabolic 445 pathways. These data suggest further functional and mechanistic experiments to validate 446 HOXA10-AS as a potential therapeutic target. The integrative analysis and experimental valida-447 tion data lend confidence to our overall catalogue of lncRNAs. However, our analysis remains 448 inconclusive to whether all or most candidate lncRNAs are functional in cancer cells or alterna-449 tively represent passive indicators of transcriptional activity. On the one hand, functionally inac-450 tive 'passenger' lncRNAs may be modulated transcriptionally or epigenetically as part of global 451 gene regulatory programs that control hallmark cancer pathways such as proliferation. These 452 markers of large regulatory programs would be expected to outperform any prognostic models 453 based on individual protein-coding genes. For example, we observed that a subset of lncRNAs 454 with hazardous risk profiles were sharply up-regulated in high-risk tumors and completely si-455 lenced in lower-risk tumors. These lncRNAs may be epigenetically repressed in the majority of 456 tumors and aberrantly activated in the high-risk minority group of tumors. Such a binary zero-457 dichotomization pattern is a promising property for biomarker development owing to a natural 458 threshold separating high-risk and low-risk patients, although further validation in independent 459 cohorts is required. On the other hand, a subset prognostic lncRNAs may be functional in cells 460 and act as functional 'drivers' that activate oncogenic processes or inhibit tumor suppressive 461 pathways through interactions with DNA, RNA and proteins. However, further experiments are 462 needed to validate the prognostic lncRNAs as drivers of cancer phenotypes, such as large-scale 463 genome editing screens that are increasingly targeting the non-coding genome encoding 464 lncRNAs [60] . Our findings of prognostic lncRNAs are ultimately limited by the transcriptional 465 and clinical information that was available for inference and validation. The TCGA tumor cohorts 466 that we studied are under-represented in rare and early-stage malignancies and the available 467 clinical variables and patient follow-up data are limited. It is plausible that lncRNA transcription 468 in cancers is associated with unrecorded environmental, genetic and phenotypic variables that 469 confounded our inference of prognostic markers. We used RNA-seq datasets that had been op-470 timized for mRNA quantification and thus additional lncRNAs likely remain uncharacterized or lie 471 below the detection limit of RNA-sequencing protocols. Future multi-omics datasets with deep 472 clinical profiles of patients will enable further discoveries and validation of non-coding RNAs. 473
Our study is a step towards systematic characterization of non-coding RNA genes as molecular 474 biomarkers and functional regulators of oncogenesis. 
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Data Collection 496
We downloaded RNA-seq data of the TCGA project for 32 tumor types from the Genome Data 497 Commons (https://portal.gdc.cancer.gov). Overall survival data was retrieved from the latest 498 publication of the TCGA PanCanAtlas project [22, 29] . We selected 29 cancer types where co-499 horts of at least 50 patients were available. We only analyzed one tumor specimen per patient 500 and maintained the tumor with a smaller TCGA serial number for patients with multiple speci-501 mens. Additional information on patient clinical variables such as alcohol consumption, smoking 502 status and molecular subtypes was downloaded using the R package TCGABiolinks [47] . We 503 intersected clinical information and transcript abundance data for each cancer type and retained 504 patient cohorts where matched datasets were available. For lncRNA annotations, we down-505 loaded the latest comprehensive annotation set of 5' lncRNA CAGE peaks from the FANTOM-506 CAT project [2] . We studied 5,785 lncRNAs that were annotated by FANTOM-CAT and the 507 ENSEMBL database and for which RNA abundance data were available in TCGA . 508
Processing TCGA RNA-seq data 509
For all cancer types of the TCGA dataset, we retrieved processed RNA-seq files as FPKM-UQ 510 measurements and raw counts from the Genome Data Commons website. lncRNAs often have 511 low transcript abundance and we first removed the lncRNAs that were not detected in any pa-512 tient tumor sample across all cohorts in TCGA RNA-seq data (n=94). Further, we evaluated me-513 dian transcript abundance of each lncRNA in every cancer type and included two classes of 514 lncRNAs in further analyses. First, we included lncRNAs with a median FPKM-UQ above 0. 515 Second, we also included a set of lncRNAs with binary transcript abundance profiles. These 516 lncRNAs showed median transcript abundance of zero FPKM-UQ representing the majority of 517 tumor samples, while a minority of tumor samples (at least 15) showed transcript abundance of 518 at least 100 FPKM-UQ. To evaluate tissue specificity of lncRNA transcription profiles, we used 519 the UMAP (Uniform Manifold Approximation and Projection) dimension reduction method [31] 520 and the corresponding R package to perform clustering of log1p-transformed FPKM-UQ lncRNA 521 transcript abundance values across the entire TCGA cohort. 522
Training survival models and evaluating generalizability 523
For each cancer type, we evaluated the association between all lncRNAs and overall patient 524 survival. We also evaluated the association between available clinical variables and overall sur-525 vival for comparison. For each cancer type, we split samples randomly into two groups, with 526 70% as the training set and 30% as the test set. Patients within each training cohort were me-527 dian-dichotomized by the transcript abundance of each lncRNA. In case of lncRNAs with me-528 dian transcript abundance of zero, patients with lncRNA transcript abundance above zero were 529 labeled as high-abundance and those with zero abundance were labeled as low-abundance. 530
We used the elastic net framework with a Cox proportional hazards link function to train patient 531 survival models and to perform feature selection. All univariate models were built using the R 532 package "survival". Elastic net modelling was performed using the R package "glmnet" where 533 the penalty hyperparameter λ was determined by fivefold cross-validation within each training 534 set. We used the fixed hyperparameter value α=0.5 for the elastic net model. We employed 535 1000-fold cross-validation with 70/30% random split of training and testing data for each cancer 536 type. Within each fold, initial elastic-net multivariate models included as predictors all lncRNAs 537 that were univariately survival-associated in the training set (univariate Cox proportional-haz-538 ards (PH) P<0.05). Feature selection during model fitting and regularization determined a non-539 redundant subset of lncRNAs as predictors in the training data. Subsequent cross-validation 540 evaluated the models using concordance index (c-index), an accuracy measure extended to 541 survival analysis [33] . The multivariate Cox PH elastic net models were then applied to the re-542 maining 30% of the test set to obtain a concordance index (c-index) using the R package "sur-543 vcomp". Besides lncRNA-based predictors, clinical variables that were available for each cancer 544 types were also used to build a multivariate model using the training set and applied on test set 545 in a similar manner. Of clinical variables, patient age was always available for all tumor types in 546 TCGA, while other features such as tumor stage, grade and ethnicity were available for a subset 547 of cancer types. Lastly, the available clinical variables were integrated with the lncRNA tran-548 script abundance profiles selected by the elastic net into one multivariate model (the combined 549 model) that was also trained and tested separately. Thus, there were three distinct performance 550 metrics (c-indices) obtained overall for each round of training. The entire outlined process was 551 repeated 1000 times, randomly splitting the data at each iteration. For each cancer type, we 552 subsequently compared the three distributions of c-indices using the two-sided U test to a set of 553 reference models that only utilized clinical variables for survival predictions. Finally, to assess 554 the performance of our models on random data, we shuffled survival outcome across all TCGA 555 patients of a given cancer type while maintaining the order of all predictor variables (lncRNAs 556 and clinical variables). This permutation strategy disrupted the association of survival infor-557 mation and molecular and clinical predictors, The analysis of this simulated data allowed us to 558 evaluate the statistical calibration of our method. We generated 100 random datasets and con-559 ducted 100 cross-validations on each of these datasets. We compared c-indices between mod-560 els fitted using shuffled outcome data and real outcome data using a two-sided U-test. As ex-561 pected, we found considerably lower performance of our models on random data that centered 562 on the expected performance values of random predictors (c≈0.5), indicating that our models 563 were well calibrated and not prone to statistical inflation and overfitting. 564
Selecting top prognostic lncRNAs 565
To prioritize lncRNAs, we summarized the number of times each lncRNA was maintained as a 566 prognostic feature in all the elastic-net survival models across cross-validations. To obtain the 567 most consistent candidates, we considered the lncRNAs in each cancer type that were included 568 in at least 50% (≥500/1000) of iterations. This list of lncRNAs was further evaluated individually. 569
For validation, we fitted multivariate Cox PH models using each lncRNA candidate together with 570 available clinical variables in respective cancer cohorts to confirm that the prognostic effect of 571 lncRNAs remained present even when accounting for common clinical variables. We also evalu-572 ated Schoenfeld residuals to confirm that the proportionality assumption of the Cox-PH model 573 was met ( Supplementary Table 3 ). Finally, we removed a small subset of candidate lncRNAs 574 that showed opposing hazards in different cancer types. To evaluate the performance of individ-575 ual lncRNA candidates within the TCGA dataset, we conducted a second round of internal 576 cross-validation. Using one lncRNA candidate at a time, we split the respective cancer patient 577 cohort into training (70%) and testing samples (30%) as described above. Univariate Cox PH 578 models were fitted and evaluated on the test datasets to obtain a distribution of c-indices for 579 each lncRNA candidate. Similarly, we conducted internal cross-validation of clinical variables as 580 a baseline reference, by fitting multivariate Cox PH models and evaluating their performance on 581 test sets using the c-index. We also compared combined models where clinical variables were 582 used together with lncRNA transcript abundance profiles for patient survival prediction. These 583 distributions of c-indices were compared using the two-sided Wilcoxon rank-sum tests and re-584 sulting P-values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) proce-585 dure [61] . 586
Validating prognostic lncRNAs in additional cohort of hepatocellular carcinoma 587
We used an independent dataset of transcriptomics and patient clinical information available in 588 the ICGC/TCGA Pan-cancer Analysis of Whole Genomes (PCAWG) project [20] . We focused 589 on the liver cancer cohort and removed any patient samples profiled in the TCGA project to cre-590 ate an entirely independent validation cohort comprising primarily of liver cancers (hepatocellu-591 lar carcinomas, HCC) of Japanese individuals [62] , resulting in a cohort of 42 tumors with uni-592 formly processed RNA-seq data [63] . Twelve lncRNAs identified in the TCGA LIHC cohort were 593 queried for prognostic signals in the validation cohort. Within the validation cohort, we consid-594 ered lncRNAs with FPKM-UQ values greater than 0.05 measured in at least five patients. We 595 dichotomized patients by lncRNA transcript abundance as described above. To evaluate signifi-596 cance of patient survival associations, we fitted univariate Cox-PH models with binary predictors 597 reflecting lncRNA transcript abundance and plotted their Kaplan-Meier survival curves using the 598 'Survival' and 'survminer' packages in R. We considered those lncRNAs with nominal P-values 599 from Wald tests as significant (P < 0.05). 600
Comparing survival associations of lncRNAs and adjacent protein-coding genes 601
We identified protein-coding genes that were located within 10,000 bps of lncRNA genes using 602 the Genome Reference Consortium Human Build 38 (GRCh38) and the bedtools software [64] . 603
We identified pairs of 96 lncRNAs and 147 protein-coding genes that we evaluated further for 604 differences in patient survival associations. For each pair, we fitted univariate Cox-PH models 605 using median-dichotomized lncRNA transcript abundance labels as described above, and com-606 pared these to Cox-PH models fitted using median-dichotomized transcript abundance values of 607 corresponding protein-coding genes. We compared the sets of two models using cross-valida-608 tion performance (i.e., c-indices) and also model fits (i.e., FDR-adjusted P-values from the Wald 609 test). We also fitted multivariate models using transcript abundance values of both the protein-610 coding gene and the lncRNA gene, and compared those models to univariate models of protein-611 coding genes using ANOVA. Multiple testing correction was performed using the Hochberg FDR procedure. 613 lncRNA associations with clinical and molecular tumor subtypes 614
We conducted a systematic analysis of clinical and molecular subtypes of TCGA tumors using 615 data curated in the R package TCGABiolinks [47] . These clinical and molecular features in-616 cluded basic clinical variables included in our elastic net framework described above (patient 617 age, sex and tumor stage and/or grade, etc. as available in TCGA), and additional variables 618 such as molecular subtypes, specific prognostic mutations and tumor histology annotations. 619
These comprehensive sample-specific annotations were only available for 12/21 cancer types 620 for which high-confidence prognostic lncRNAs were predicted, and we further analyzed only the 621 113/179 lncRNAs predicted in these cancer types. For each lncRNA, we evaluated whether the 622 transcript abundance was significantly associated with clinical and molecular features. Dichoto-623 mized lncRNA transcript abundance profiler (high vs. low) were compared to clinical and molec-624 ular features using chi-squared tests as most clinical and molecular variables per patient were 625 recorded as binary categories. For numerical clinical and molecular variables (such as age), we 626 analyzed the spearman correlation between the variables and lncRNA transcript abundance. 627
We adjusted P-values for multiple testing using the Benjamini-Hochberg FDR procedure and 628 selected significant associations (FDR < 0.05). All clinical features from the analysis that were 629 significantly associated with our lncRNA candidates were also evaluated for associations with 630 overall patient survival. For the lncRNAs associated with at least one clinical or molecular fea-631 ture, we extracted the corresponding (c-index) from a Cox-PH model (model 1). Next, we fitted 632 univariate Cox-PH models with the clinical or molecular feature as a predictor of overall patient 633 survival within the respective cancer cohort. For each model we extracted its c-index, HR and 634 Wald test P-value (model 2). Finally, we fitted a multivariate model with both the clinical or mo-635 lecular feature with the lncRNA transcript abundance profile that it was associated with (model 636 3). This allowed us quantify the combination of lncRNA transcript abundance and previously an-637 notated clinical and molecular features. Tests with Cox PH models were defined as: 638
Test #1: Anova (model 1, model 3), to assess the improvement of the survival associa-639 tion when using both lncRNA transcript abundance and clinical/molecular features as 640 predictors, compared to lncRNA-based predictors alone. 641
Test #2: Anova (model 2, model 3), to assess the improvement of the survival associa-642 tion when using both lncRNA transcript abundance and clinical/molecular features as 643 predictors, compared to clinical and molecular features as predictors alone. 644
To obtain the final list of lncRNA-associated clinical and molecular features that showed signifi-645 cant improvement in survival association in combination with lncRNA transcript abundance, we 646 considered two criteria: a significant likelihood ratio test (FDR < 0.05) from the Test #2 above, 647
and an absolute increase in c-index in cross-validation experiments. 648
Pathway enrichment analysis of lncRNA-associated protein-coding genes 649 of knocking down HOXA10-AS, we purposefully avoided this region in siRNA design and in-698 stead selected siRNAs targeting exon2 of HOXA10-AS, a region unique to HOXA10-AS and not 699 overlapping with HOXA10. We confirmed successful knock-down of HOXA10-AS by RT-PCR 700 using primers flanking exon2 of HOXA10-AS. With depletion of HOXA10-AS we did not observe 701 a significant change in HOXA10 transcript abundance in either our RT-qPCR or RNA-seq exper-702 iments. 703
PrestoBlue Cell Viability assay 704
PrestoBlue Cell Viability assays (A13262, Thermo Fisher Scientific) were performed as per 705 manufacturer's protocol. Briefly, 5,000 cells were seeded into each well of 96-well plates on day 706 0 of DsiRNA transfection. On each day of viability assay, cells were incubated with 100ul fresh 707 complete medium with the PrestoBlue reagent for 40 min. Then the fluorescence readout was 708 obtained using a SpectraMax Gemini EM Microplate Reader (Molecular Devices) with the exci-709 tation/emission wavelengths set at 544/590 nm. Cell viability is reported at the 6-day timepoint 710 of the experiment. 711 RNA-seq data processing analysis was carried out using standard procedures and custom R 735 scripts. First, sequenced reads were aligned to the human reference genome GRCh38 and 736 passed through a quality assessment pipeline using the package Rsubread [70] . High read 737 mappability was observed in the dataset and all replicates were included. Next, the mapped 738 reads were counted across all genes using the edgeR R package [71] . Counts-per-million 739 (CPM) values were calculated for all genes to normalize read counts resulting from per-replicate 740 differences of sequencing depths. We focused on transcript abundance values of consensus 741 coding sequence genes (CCDS) database V22 [72] and filtered other classes of genes from our 742 dataset. We also filtered lowly expressed genes and only included genes with above-baseline 743 transcript abundance (CPM > 0.5) in at least two replicates. Next, trimmed mean of M values 744 normalization was performed to remove composition bias between libraries [73] . Two design 745 matrices for comparing the three technical replicates corresponding to distinct siRNAs (H1 and 746 H4, respectively) against the three replicates of the control siRNA (NT1) were generated. Tran-747 script abundance values were subsequently transformed with the voom procedure of the limma 748 package [65] . Differential transcript abundance analysis was conducted by first fitting a linear 749 model to the voom-transformed CPM values. Next, an empirical Bayes shrinkage method was 750 performed on the variances and a statistical test using a pre-defined a fold-change (FC) thresh-751 old (abs(log2(FC)) > 1.2) was conducted to estimate statistical significance of differential tran-752 script abundance, using the TREAT method [56] . The resulting P-values from the two siRNA ex-753 periments (H1 vs NT1; H4 vs NT1) were merged using the Brown method [74] to prioritize 754 genes differentially regulated in both HOXA10-AS depletion experiments and to deprioritize spe-755 cific off-targets of each of the siRNAs. The merged p-values were corrected for multiple testing 756 using the Benjamini-Hochberg procedure and significant genes were selected (FDR < 0.05). To 757 evaluate the agreement of the two siRNAs, we conducted a Pearson correlation test of log10-758 transformed p-values from the two siRNA experiments. We confirmed that a very small number 759 of significant genes showed opposite fold-changes in the two experiments (3 genes or 0.12%), 760 indicating a strong agreement of the two siRNAs (H1, H4) in depleting HOXA10-AS and an 761 overall lack of major off-target effects. Pathway enrichment analysis of differentially expressed 762 genes was conducted using ActivePathways [48] with all genes and corresponding P-values 763 from the two siRNA experiments (H1 vs NT1; H4 vs NT1) as input and default parameter set-764 tings (FWER < 0.05). Enrichment maps were generated in Cytoscape using the EnrichmentMap 765 app and standard protocols [47] . Pathway-annotated genes from the ActivePathways analysis 766 were curated for known glioma genes using the COSMIC Cancer Census database [35] and 767 previous GBM sequencing studies [57, 58] . 768 769
